- Home
- IVP vs WINT Comparison
IVP vs WINT Comparison
Compare IVP & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- WINT
- Stock Information
- Founded
- IVP 2020
- WINT 1992
- Country
- IVP United States
- WINT United States
- Employees
- IVP N/A
- WINT N/A
- Industry
- IVP Diversified Commercial Services
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVP Miscellaneous
- WINT Health Care
- Exchange
- IVP Nasdaq
- WINT Nasdaq
- Market Cap
- IVP 4.0M
- WINT 4.8M
- IPO Year
- IVP 2023
- WINT 1995
- Fundamental
- Price
- IVP $0.87
- WINT $2.80
- Analyst Decision
- IVP
- WINT Hold
- Analyst Count
- IVP 0
- WINT 1
- Target Price
- IVP N/A
- WINT $18.00
- AVG Volume (30 Days)
- IVP 3.5M
- WINT 860.1K
- Earning Date
- IVP 08-14-2024
- WINT 08-19-2024
- Dividend Yield
- IVP N/A
- WINT N/A
- EPS Growth
- IVP N/A
- WINT N/A
- EPS
- IVP N/A
- WINT N/A
- Revenue
- IVP $17,125,400.00
- WINT N/A
- Revenue This Year
- IVP N/A
- WINT N/A
- Revenue Next Year
- IVP N/A
- WINT N/A
- P/E Ratio
- IVP N/A
- WINT N/A
- Revenue Growth
- IVP 15.13
- WINT N/A
- 52 Week Low
- IVP $0.66
- WINT $2.75
- 52 Week High
- IVP $242.00
- WINT $27.00
- Technical
- Relative Strength Index (RSI)
- IVP 34.24
- WINT 29.02
- Support Level
- IVP $0.66
- WINT $10.20
- Resistance Level
- IVP $1.47
- WINT $10.90
- Average True Range (ATR)
- IVP 0.60
- WINT 1.37
- MACD
- IVP -0.15
- WINT -1.16
- Stochastic Oscillator
- IVP 5.44
- WINT 0.48
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.